Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 5 years
- Director since
- 2023
5 years of board service in total across 2 boards, counting each seat separately. Longest: Citius Pharmaceuticals Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Citius Oncology Inc. September 29, 202689.1%
-
Citius Pharmaceuticals Inc. April 6, 202669.1%
-
Citius Pharmaceuticals Inc. March 10, 202571.1%
-
Citius Pharmaceuticals Inc. March 12, 202484.5%
-
Citius Pharmaceuticals Inc. February 7, 202391.0%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 19, 2025 | Citius Oncology Inc. | Grant or award | +300,000 | — | — |
| Mar 13, 2024 | Citius Pharmaceuticals Inc. | Option exercise | +2,415 | $0.02 | $48 |
| Mar 13, 2024 | Citius Pharmaceuticals Inc. | Shares withheld for tax | −48 | $0.75 | $36 |
Questions about Eugene Myron Holuka
What boards is Eugene Myron Holuka on?
Eugene Myron Holuka sits on the boards of Citius Oncology Inc. and Citius Pharmaceuticals Inc.
How long has Eugene Myron Holuka served on boards?
Our records show at least 5 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.